Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form
As of April 1st VIVO Scientific Profiles will no longer updated for faculty, and the link to VIVO will be removed from the library website. Faculty profile pages will continue to be updated via Interfolio. VIVO will continue being used behind the scenes to update graduate student profiles. Please contact helplib@scripps.edu if you have questions.
How to download citations from VIVO | Alternative profile options

Aldehyde dehydrogenase inhibitors: A comprehensive review of the pharmacology, mechanism of action, substrate specificity, and clinical application

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Koppaka, V.
  • Thompson, D. C.
  • Chen, Y.
  • Ellermann, M.
  • Nicolaou, K.C.
  • Juvonen, R. O.
  • Petersen, D.
  • Deitrich, R. A.
  • Hurley, T. D.
  • Vasiliou, V.

publication date

  • July 2012

journal

  • Pharmacological Reviews  Journal

abstract

  • Aldehyde dehydrogenases (ALDHs) belong to a superfamily of enzymes that play a key role in the metabolism of aldehydes of both endogenous and exogenous derivation. The human ALDH superfamily comprises 19 isozymes that possess important physiological and toxicological functions. The ALDH1A subfamily plays a pivotal role in embryogenesis and development by mediating retinoic acid signaling. ALDH2, as a key enzyme that oxidizes acetaldehyde, is crucial for alcohol metabolism. ALDH1A1 and ALDH3A1 are lens and corneal crystallins, which are essential elements of the cellular defense mechanism against ultraviolet radiation-induced damage in ocular tissues. Many ALDH isozymes are important in oxidizing reactive aldehydes derived from lipid peroxidation and thereby help maintain cellular homeostasis. Increased expression and activity of ALDH isozymes have been reported in various human cancers and are associated with cancer relapse. As a direct consequence of their significant physiological and toxicological roles, inhibitors of the ALDH enzymes have been developed to treat human diseases. This review summarizes known ALDH inhibitors, their mechanisms of action, isozyme selectivity, potency, and clinical uses. The purpose of this review is to 1) establish the current status of pharmacological inhibition of the ALDHs, 2) provide a rationale for the continued development of ALDH isozyme-selective inhibitors, and 3) identify the challenges and potential therapeutic rewards associated with the creation of such agents.

subject areas

  • Aldehyde Dehydrogenase
  • Animals
  • Binding Sites
  • Clinical Trials as Topic
  • Enzyme Inhibitors
  • Humans
  • Models, Molecular
  • Molecular Structure
  • Substrate Specificity
scroll to property group menus

Identity

PubMed Central ID

  • PMC3400832

International Standard Serial Number (ISSN)

  • 0031-6997

Digital Object Identifier (DOI)

  • 10.1124/pr.111.005538

PubMed ID

  • 22544865
scroll to property group menus

Additional Document Info

start page

  • 520

end page

  • 539

volume

  • 64

issue

  • 3

©2022 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support